Literature DB >> 27810895

A Novel Role for Pyruvate Kinase M2 as a Corepressor for P53 during the DNA Damage Response in Human Tumor Cells.

Li Xia1, Xin-Ran Wang1, Xiao-Ling Wang1, Su-Hui Liu1, Xiao-Wei Ding1, Guo-Qiang Chen2,3, Ying Lu4.   

Abstract

The pyruvate kinase (PK) is a rate-limiting glycolytic enzyme catalyzing the dephosphorylation of phosphoenolpyruvate to pyruvate, yielding one molecule of ATP. The M2 isoform of PK (PKM2) is predominantly expressed in normal proliferating cells and tumors, and both metabolic and non-metabolic activities for the enzyme in promoting tumor cell proliferation have been identified. However, the exact roles of PKM2 in tumor initiation, growth and maintenance are not yet fully understood. Using immunoprecipitation-coupled LC-MS/MS in MCF7 cells exposed to DNA-damaging agent, we report that the nuclear PKM2 interacts directly with P53 protein, a critical safeguard for genome stability. Specifically, PKM2 inhibits P53-dependent transactivation of the P21 gene by preventing P53 binding to the P21 promoter, leading to a nonstop G1 phase. As a result, PKM2 expression provides a growth advantage for tumor cells in the presence of a DNA damage stimulus. In addition, PKM2 interferes with phosphorylation of P53 at serine 15, known to stimulate P53 activity by the ATM serine/threonine kinase. These findings reveal a new role for PKM2 in modulating the DNA damage response and illustrate a novel mechanism of PKM2 participating in tumorigenesis.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  DNA damage; DNA damage response; p53; pyruvate kinase; transcription corepressor

Mesh:

Substances:

Year:  2016        PMID: 27810895      PMCID: PMC5207082          DOI: 10.1074/jbc.M116.737056

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

2.  Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase.

Authors:  Xueliang Gao; Haizhen Wang; Jenny J Yang; Xiaowei Liu; Zhi-Ren Liu
Journal:  Mol Cell       Date:  2012-02-02       Impact factor: 17.970

3.  Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells.

Authors:  H Nagasawa; C Y Li; C G Maki; A C Imrich; J B Little
Journal:  Cancer Res       Date:  1995-05-01       Impact factor: 12.701

4.  The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth.

Authors:  Heather R Christofk; Matthew G Vander Heiden; Marian H Harris; Arvind Ramanathan; Robert E Gerszten; Ru Wei; Mark D Fleming; Stuart L Schreiber; Lewis C Cantley
Journal:  Nature       Date:  2008-03-13       Impact factor: 49.962

5.  Cell-state-specific metabolic dependency in hematopoiesis and leukemogenesis.

Authors:  Ying-Hua Wang; William J Israelsen; Dongjun Lee; Vionnie W C Yu; Nathaniel T Jeanson; Clary B Clish; Lewis C Cantley; Matthew G Vander Heiden; David T Scadden
Journal:  Cell       Date:  2014-09-11       Impact factor: 41.582

6.  Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation.

Authors:  Weiwei Yang; Yan Xia; Haitao Ji; Yanhua Zheng; Ji Liang; Wenhua Huang; Xiang Gao; Kenneth Aldape; Zhimin Lu
Journal:  Nature       Date:  2011-12-01       Impact factor: 49.962

7.  Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression.

Authors:  Michael S Goldberg; Phillip A Sharp
Journal:  J Exp Med       Date:  2012-01-23       Impact factor: 14.307

8.  PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.

Authors:  C Papadaki; M Sfakianaki; E Lagoudaki; G Giagkas; G Ioannidis; M Trypaki; E Tsakalaki; A Voutsina; A Koutsopoulos; D Mavroudis; V Georgoulias; J Souglakos
Journal:  Br J Cancer       Date:  2014-09-18       Impact factor: 7.640

9.  HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo.

Authors:  Hongbiao Huang; Ningning Liu; Changshan Yang; Siyan Liao; Haiping Guo; Kai Zhao; Xiaofen Li; Shouting Liu; Lixia Guan; Chunjiao Liu; Li Xu; Change Zhang; Wenbin Song; Bing Li; Ping Tang; Q Ping Dou; Jinbao Liu
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

10.  Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis.

Authors:  Dimitrios Anastasiou; Yimin Yu; William J Israelsen; Jian-Kang Jiang; Matthew B Boxer; Bum Soo Hong; Wolfram Tempel; Svetoslav Dimov; Min Shen; Abhishek Jha; Hua Yang; Katherine R Mattaini; Christian M Metallo; Brian P Fiske; Kevin D Courtney; Scott Malstrom; Tahsin M Khan; Charles Kung; Amanda P Skoumbourdis; Henrike Veith; Noel Southall; Martin J Walsh; Kyle R Brimacombe; William Leister; Sophia Y Lunt; Zachary R Johnson; Katharine E Yen; Kaiko Kunii; Shawn M Davidson; Heather R Christofk; Christopher P Austin; James Inglese; Marian H Harris; John M Asara; Gregory Stephanopoulos; Francesco G Salituro; Shengfang Jin; Lenny Dang; Douglas S Auld; Hee-Won Park; Lewis C Cantley; Craig J Thomas; Matthew G Vander Heiden
Journal:  Nat Chem Biol       Date:  2012-10       Impact factor: 15.040

View more
  15 in total

1.  Endothelial pyruvate kinase M2 maintains vascular integrity.

Authors:  Boa Kim; Cholsoon Jang; Harita Dharaneeswaran; Jian Li; Mohit Bhide; Steven Yang; Kristina Li; Zolt Arany
Journal:  J Clin Invest       Date:  2018-09-17       Impact factor: 14.808

Review 2.  The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.

Authors:  Dexter L Puckett; Mohammed Alquraishi; Winyoo Chowanadisai; Ahmed Bettaieb
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

3.  Pyruvate Kinase M2 Protects Heart from Pressure Overload-Induced Heart Failure by Phosphorylating RAC1.

Authors:  Le Ni; Bowen Lin; Lingjie Hu; Ruoyu Zhang; Fengmei Fu; Meiting Shen; Jian Yang; Dan Shi
Journal:  J Am Heart Assoc       Date:  2022-06-03       Impact factor: 6.106

Review 4.  A critical review of the role of M2PYK in the Warburg effect.

Authors:  Robert A Harris; Aron W Fenton
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-01-29       Impact factor: 10.680

5.  MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.

Authors:  Jianan Chen; Yan Yu; Xiaolong Chen; Yuting He; Qiuyue Hu; Hongqiang Li; Qicai Han; Fang Ren; Juan Li; Chao Li; Jie Bao; Zhigang Ren; Zhenfeng Duan; Guangying Cui; Ranran Sun
Journal:  Cell Prolif       Date:  2018-08-13       Impact factor: 6.831

Review 6.  A short review on cross-link between pyruvate kinase (PKM2) and Glioblastoma Multiforme.

Authors:  Harkomal Verma; Ravi P Cholia; Sharanjot Kaur; Monisha Dhiman; Anil K Mantha
Journal:  Metab Brain Dis       Date:  2021-03-02       Impact factor: 3.584

7.  Pyruvate kinase M2 phosphorylates H2AX and promotes genomic instability in human tumor cells.

Authors:  Li Xia; Kang Qin; Xin-Ran Wang; Xiao-Ling Wang; Ai-Wu Zhou; Guo-Qiang Chen; Ying Lu
Journal:  Oncotarget       Date:  2017-11-17

Review 8.  The Krebs Cycle Connection: Reciprocal Influence Between Alternative Splicing Programs and Cell Metabolism.

Authors:  Giuseppe Biamonti; Lucia Maita; Alessandra Montecucco
Journal:  Front Oncol       Date:  2018-09-26       Impact factor: 6.244

9.  2-Bromopalmitate targets retinoic acid receptor alpha and overcomes all-trans retinoic acid resistance of acute promyelocytic leukemia.

Authors:  Ying Lu; Jin-Song Yan; Li Xia; Kang Qin; Qian-Qian Yin; Hong-Tao Xu; Meng-Qing Gao; Xiao-Ning Qu; Yu-Ting Sun; Guo-Qiang Chen
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

10.  ANP32B-mediated repression of p53 contributes to maintenance of normal and CML stem cells.

Authors:  Shuo Yang; Xiao-Na Zhu; Hui-Lin Zhang; Qian Yang; Yu-Sheng Wei; Di Zhu; Meng-Di Liu; Shao-Ming Shen; Li Xia; Ping He; Meng-Kai Ge; Yi-Lian Pan; Meng Zhao; Ying-Li Wu; Jun-Ke Zheng; Guo-Qiang Chen; Yun Yu
Journal:  Blood       Date:  2021-12-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.